Gary Bridger
Chief Tech/Sci/R&D Officer bei LIMINAL BIOSCIENCES INC.
Vermögen: 71 817 $ am 31.03.2024
Profil
Gary J.
Bridger founded AnorMED, Inc. in 1996, where he worked as Chief Scientific Officer, VP-R&D from 2000 to 2016.
Dr. Bridger also currently works at Liminal BioSciences, Inc., as Director & Chief Scientific Officer from 2022, Expansion Therapeutics, Inc., as Director from 2022, X4 Pharmaceuticals, Inc., as Director, and Five Corners Capital, Inc., as General Partner from 2013.
Dr. Bridger also formerly worked at Arsanis, Inc., as Director, X4 Pharmaceuticals, Inc., as Director, Celator Pharmaceuticals Corp., as Director, Lundbeck Seattle BioPharmaceuticals, Inc., as Independent Director from 2013 to 2016, Aquinox Pharmaceuticals, Inc., as Independent Director from 2013 to 2019, NeurAxon, Inc., as Director, Presidio Advisors, Inc., as Director, Genzyme Corp., as Senior Vice President-Research & Development from 2006 to 2007, Xenon Pharmaceuticals, Inc., as Executive Vice President-Research & Development from 2013 to 2015, and Ventures West Management, Inc., as Venture Partner from 2010 to 2012.
Dr. Bridger received his doctorate degree in 1987 from the University of Manchester Institute of Science & Technology.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
X4 PHARMACEUTICALS, INC.
0,03% | 13.06.2023 | 51 667 ( 0,03% ) | 71 817 $ | 31.03.2024 |
Aktive Positionen von Gary Bridger
| Unternehmen | Position | Beginn |
|---|---|---|
| X4 PHARMACEUTICALS, INC. | Director/Board Member | 01.10.2018 |
| LIMINAL BIOSCIENCES INC. | Chief Tech/Sci/R&D Officer | 09.11.2022 |
Five Corners Capital, Inc.
 Five Corners Capital, Inc. Investment ManagersFinance Five Corners Capital Inc (Five Corners Capital) is a venture capital firm founded in 2013 by Kenneth Galbraith and Gary Bridger. The firm is headquartered in British Columbia, Canada. | Private Equity Investor | 02.10.2013 |
Expansion Therapeutics, Inc.
 Expansion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Expansion Therapeutics, Inc. manufactures pharmaceutical products. The company is headquartered in Del Mar, CA. | Director/Board Member | 19.01.2022 |
Ehemalige bekannte Positionen von Gary Bridger
| Unternehmen | Position | Ende |
|---|---|---|
Aquinox Pharmaceuticals, Inc.
 Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | Director/Board Member | 09.08.2019 |
AnorMED, Inc.
 AnorMED, Inc. Pharmaceuticals: MajorHealth Technology AnorMED is a chemistry-based biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, HIV and oncology. The Company has four products in clinical development and a research program focused on a novel class of compounds that target specific chemokine receptors known to be involved in a variety of diseases. | Founder | 01.11.2016 |
| ALDER BIOPHARMACEUTICALS, INC. | Director/Board Member | 01.01.2016 |
| XENON PHARMACEUTICALS INC. | Chief Tech/Sci/R&D Officer | 01.02.2015 |
Ventures West Management, Inc.
 Ventures West Management, Inc. Investment ManagersFinance Ventures West Management, Inc. is venture capital firm headquartered in Vancouver, British Columbia with additional offices in Toronto, Montréal and Kanata, Ontario | Private Equity Investor | 01.06.2012 |
Ausbildung von Gary Bridger
| University of Manchester Institute of Science & Technology | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| LIMINAL BIOSCIENCES INC. | Health Technology |
| XENON PHARMACEUTICALS INC. | Health Technology |
| X4 PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 12 |
|---|---|
AnorMED, Inc.
AnorMED, Inc. Pharmaceuticals: MajorHealth Technology AnorMED is a chemistry-based biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, HIV and oncology. The Company has four products in clinical development and a research program focused on a novel class of compounds that target specific chemokine receptors known to be involved in a variety of diseases. | Health Technology |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Arsanis, Inc.
 Arsanis, Inc. BiotechnologyHealth Technology Arsanis, Inc. operates as a clinical-stage biotechnology company, which engages in provision of monoclonal antibody immunotherapies to address serious infectious diseases. The company was founded by Eszter Nagy, Tillman U. Gerngross, and Errik B. Anderson on August 2, 2010 and is headquartered in Waltham, MA. | Health Technology |
X4 Pharmaceuticals, Inc. /Old/
 X4 Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology X4 Pharmaceuticals, Inc. develops novel therapeutics designed to improve immune cell trafficking to treat cancer and rare diseases. It offers X4P-001-RD, X4P-001-IO, and X4P-002. The company was founded by Paula Ragan, Alan Walts, Michael Gilman, Henri Termeer, Keith Flaherty, Renato Skerlj, and Richard Peters in July 2014 and is headquartered in Cambridge, MA. | Health Technology |
Ventures West Management, Inc.
Ventures West Management, Inc. Investment ManagersFinance Ventures West Management, Inc. is venture capital firm headquartered in Vancouver, British Columbia with additional offices in Toronto, Montréal and Kanata, Ontario | Finance |
Celator Pharmaceuticals Corp.
 Celator Pharmaceuticals Corp. BiotechnologyHealth Technology Celator Pharmaceuticals Corp. is an oncology-based biopharmaceutical company. It focuses on a proprietary technology platform which evaluates combinations of anti-cancer drugs for enhanced anti-cancer activity. The company was founded by Lawrence David Mayer and is headquartered in Vancouver, Canada. | Health Technology |
Lundbeck Seattle BioPharmaceuticals, Inc.
 Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Seattle BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Its product includes Eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA. | Health Technology |
Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | Health Technology |
NeurAxon, Inc.
 NeurAxon, Inc. Miscellaneous Commercial ServicesCommercial Services NeurAxon, Inc. is engaged in the research and development of growing and unmet needs for chronic pain management. It is focused on developing pain therapeutics targeting neuronal Nitric Oxide Synthase (nNOS) inhibitors. The companyw as founded in 2004 and is headquartered in Mississauga, ON. | Commercial Services |
Presidio Advisors, Inc.
 Presidio Advisors, Inc. Investment ManagersFinance Presidio Advisors, Inc. provides investment advice. The private company is based in San Antonio, TX. | Finance |
Five Corners Capital, Inc.
Five Corners Capital, Inc. Investment ManagersFinance Five Corners Capital Inc (Five Corners Capital) is a venture capital firm founded in 2013 by Kenneth Galbraith and Gary Bridger. The firm is headquartered in British Columbia, Canada. | Finance |
Expansion Therapeutics, Inc.
Expansion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Expansion Therapeutics, Inc. manufactures pharmaceutical products. The company is headquartered in Del Mar, CA. | Health Technology |
